There	O
are	O
studies	O
analysing	O
the	O
iron	O
content	O
in	O
APE	O
[	O
38	O
,	O
39	O
,	O
40	O
].	O

CITEViz	B-BT
analysis	O
of	O
PBMC	O
CITE	O
-	O
Seq	O
data	O
.	O

LOS	O
:	O
length	O
of	O
stay	O
,	O
PACU	O
:	O
postoperative	O
care	O
unit	O
,	O
BMI	O
:	O
body	O
mass	O
index	O
,	O
ASA	O
:	O
American	O
association	O
of	O
anesthesiologist	O
score	O
,	O
min	O
:	O
minutes	O
,	O
d	O
:	O
days	O
,	O
COPD	O
:	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
AIDS	O
:	O
Acquired	O
Immunodeficiency	O
Syndrome	O
,	O
n	O
:	O
number	O
,	O
ENT	O
:	O
ear	O
-	O
nose	O
-	O
throat	O
,	O
non	O
-	O
or	O
:	O
non	O
operating	O
room	O

Continuous	O
detection	O
of	O
the	O
HUVEC	O
monolayer	O
for	O
the	O
addition	O
of	O
100	O
µg	O
/	O
mL	O
APE	O
to	O
the	O
culture	O
medium	O
using	O
the	O
xCelligence	O
system	O
,	O
n	O
=	O
8	O
each	O
.	O

Two	O
days	O
after	O
cell	O
seeding	O
and	O
continuous	O
cultivation	O
in	O
culture	O
medium	O
with	O
APE	O
,	O
no	O
significant	O
differences	O
in	O
viability	O
between	O
untreated	O
and	O
APE	O
-	O
treated	O
HUVECs	O
could	O
be	O
detected	O
(	O
Figure	O
5	O
).	O

Ethical	O
approval	O
for	O
Big	O
SHIFT	O
was	O
granted	O
by	O
the	O
Fiji	O
National	O
Health	O
Research	O
Ethics	O
Review	O
Committee	O
(	O
reference	O
:	O
2018	O
.	O
38	O
.	O
NOR	O
)	O
and	O
the	O
Royal	O
Children	O
’	O
s	O
Hospital	O
Human	O
Research	O
Ethics	O
Committee	O
in	O
Melbourne	O
,	O
Australia	O
(	O
reference	O
:	O
38020	O
).	O

There	O
were	O
also	O
significantly	O
more	O
viable	O
HUVECs	O
after	O
the	O
addition	O
of	O
APE	O
-	O
200	O
than	O
after	O
the	O
addition	O
of	O
AP	O
50	O
.	O

LOS	O
:	O
Length	O
of	O
stay	O
,	O
PACU	O
:	O
Post	O
anesthesia	O
care	O
unit	O
,	O
LOS	O
:	O
length	O
of	O
stay	O
,	O
PACU	O
:	O
postoperative	O
care	O
unit	O
,	O
MAP	O
:	O
mean	O
arterial	O
pressure	O
,	O
IOH	O
:	O
intraoperative	O
hypotension	O
,	O
min	O
:	O
minutes	O

We	O
applied	O
CITEViz	B-BT
to	O
a	O
peripheral	O
blood	O
mononuclear	O
cell	O
CITE	O
-	O
Seq	O
dataset	O
and	O
gated	O
for	O
several	O
major	O
blood	O
cell	O
populations	O
(	O
CD14	O
monocytes	O
,	O
CD4	O
T	O
cells	O
,	O
CD8	O
T	O
cells	O
,	O
NK	O
cells	O
,	O
B	O
cells	O
,	O
and	O
platelets	O
)	O
using	O
canonical	O
surface	O
protein	O
markers	O
.	O

In	O
addition	O
to	O
sequencing	O
assays	O
,	O
the	O
ever	O
-	O
shifting	O
landscape	O
of	O
bioinformatic	O
file	O
formats	O
can	O
affect	O
compatibility	O
with	O
CITEViz	B-BT
in	O
the	O
future	O
.	O

Since	O
the	O
essential	O
feature	O
of	O
CITEViz	B-BT
is	O
its	O
iterative	O
filtering	O
process	O
,	O
it	O
is	O
not	O
intended	O
for	O
any	O
data	O
preprocessing	O
or	O
normalization	O
.	O

The	O
1	O
%	O
trimmed	O
hLOS	O
and	O
PACU	O
-	O
LOS	O
were	O
log	O
-	O
transformed	O
for	O
use	O
as	O
dependent	O
variables	O
in	O
the	O
models	O
in	O
order	O
to	O
stabilize	O
the	O
residual	O
distribution	O
;	O
the	O
results	O
were	O
back	O
-	O
transformed	O
to	O
the	O
original	O
scale	O
for	O
graphical	O
presentation	O
.	O

The	O
highest	O
metabolic	O
activity	O
was	O
again	O
observed	O
in	O
HUVECs	O
cultured	O
with	O
APE	O
-	O
100	O
(	O
Figure	O
8	O
).	O

Prostacyclin	O
(	O
PGl2	O
)—	O
secretion	O
of	O
HUVECs	O
two	O
and	O
four	O
days	O
after	O
seeding	O
(	O
untreated	O
control	O
:	O
HUVECs	O
in	O
culture	O
medium	O
;	O
50	O
µg	O
/	O
mL	O
APE	O
:	O
HUVECs	O
in	O
culture	O
medium	O
with	O
50	O
µg	O
/	O
mL	O
APE	O
;	O
100	O
µg	O
/	O
mL	O
APE	O
:	O
HUVECs	O
in	O
culture	O
medium	O
with	O
100	O
µg	O
/	O
mL	O
APE	O
;	O
200	O
µg	O
/	O
mL	O
APE200	O
:	O
HUVECs	O
in	O
culture	O
medium	O
with	O
200	O
µg	O
/	O
mL	O
APE	O
.	O

Unlike	O
other	O
packages	O
,	O
this	O
process	O
can	O
be	O
repeated	O
to	O
the	O
nth	O
degree	O
in	O
CITEViz	B-BT
.	O

A	O
strength	O
of	O
our	O
study	O
is	O
that	O
we	O
analyzed	O
PHC	O
data	O
obtained	O
from	O
a	O
trial	O
that	O
was	O
conducted	O
among	O
the	O
entire	O
population	O
of	O
the	O
Northern	O
Division	O
of	O
Fiji	O
,	O
including	O
children	O
and	O
the	O
elderly	O
.	O

Here	O
also	O
,	O
no	O
increase	O
in	O
IL	O
-	O
6	O
concentration	O
compared	O
to	O
that	O
in	O
control	O
cells	O
occurred	O
for	O
the	O
APE	O
concentration	O
of	O
100	O
µg	O
/	O
mL	O
(	O
see	O
Figure	O
10	O
).	O

We	O
only	O
had	O
data	O
to	O
calculate	O
the	O
odds	O
ratio	O
of	O
impetigo	O
in	O
other	O
divisions	O
of	O
Fiji	O
compared	O
to	O
the	O
Northern	O
Division	O
,	O
so	O
we	O
used	O
impetigo	O
as	O
a	O
proxy	O
for	O
all	O
potentially	O
scabies	O
-	O
related	O
SSTIs	O
.	O

This	O
was	O
done	O
using	O
a	O
univariable	O
,	O
a	O
multivariable	O
logistic	O
regression	O
model	O
(	O
for	O
binary	O
outcome	O
30	O
-	O
day	O
mortality	O
)	O
and	O
two	O
linear	O
regression	O
models	O
(	O
for	O
the	O
metric	O
outcomes	O
hLOS	O
and	O
PACU	O
-	O
LOS	O
).	O

Implementation	O
of	O
CITEViz	B-BT
.	O

The	O
lowest	O
IL	O
-	O
6	O
release	O
occurred	O
in	O
untreated	O
control	O
cells	O
compared	O
to	O
those	O
in	O
APE	O
-	O
50	O
-	O
and	O
APE	O
-	O
200	O
-	O
treated	O
cells	O
.	O

Forty	O
-	O
eight	O
or	O
eighty	O
-	O
five	O
hours	O
after	O
cell	O
seeding	O
,	O
all	O
HUVECs	O
(	O
with	O
or	O
without	O
APE	O
)	O
showed	O
uniform	O
vinculin	O
expression	O
.	O

1Implementation	O
of	O
CITEViz	B-BT
.	O

The	O
endothelial	O
cells	O
reacted	O
very	O
differently	O
to	O
the	O
addition	O
of	O
APE	O
depending	O
on	O
the	O
concentration	O
of	O
the	O
extract	O
.	O

In	O
Fiji	O
,	O
two	O
pilot	O
studies	O
were	O
conducted	O
to	O
provide	O
evidence	O
on	O
MDA	O
[	O
7	O
,	O
11	O
].	O

Interestingly	O
,	O
no	O
TXA2	O
was	O
detected	O
in	O
the	O
cell	O
culture	O
supernatant	O
of	O
HUVECs	O
cultured	O
with	O
APE	O
.	O

One	O
possible	O
reason	O
could	O
be	O
the	O
supplementation	O
of	O
cells	O
with	O
iron	O
from	O
APE	O
.	O

scalepopgen	B-BT
is	O
hosted	O
on	O
GitHub	O
under	O
the	O
popgen48	O
organization	O
(	O
https	O
://	O
github	O
.	O
com	O
/	O
Popgen48	O
/	O
scalepopgen	O
)	O
and	O
released	O
under	O
MIT	O
license	O
.	O

MetaPathways	B-BT
utilizes	O
a	O
modified	O
version	O
of	O
PathoLogic	O
for	O
pathway	O
prediction	O
.	O

Extrapolating	O
the	O
data	O
from	O
the	O
Northern	O
Division	O
to	O
the	O
rest	O
of	O
Fiji	O
,	O
the	O
estimated	O
annual	O
number	O
of	O
PHC	O
presentations	O
for	O
scabies	O
and	O
related	O
SSTIs	O
was	O
82	O
,	O
183	O
(	O
Table	O
4	O
).	O

APE	O
has	O
been	O
shown	O
to	O
reduce	O
both	O
TnFα	O
and	O
TGFβ	O
[	O
53	O
,	O
54	O
].	O

Testing	O
these	O
three	O
definitions	O
of	O
IOH	O
in	O
the	O
independent	O
second	O
subset	O
confirmed	O
the	O
associations	O
of	O
IOH	O
with	O
30	O
-	O
day	O
mortality	O
,	O
hLOS	O
,	O
and	O
PACU	O
-	O
LOS	O
.	O

To	O
account	O
for	O
the	O
imminent	O
introduction	O
of	O
new	O
file	O
formats	O
or	O
data	O
structures	O
,	O
CITEViz	B-BT
was	O
modularly	O
built	O
to	O
accept	O
various	O
input	O
file	O
types	O
.	O

This	O
amount	O
is	O
more	O
than	O
double	O
the	O
estimated	O
cost	O
of	O
medicines	O
for	O
treatment	O
of	O
outpatient	O
pneumonia	O
in	O
Fiji	O
[	O
29	O
];	O
in	O
that	O
study	O
,	O
the	O
average	O
cost	O
of	O
medicines	O
ranged	O
from	O
$	O
1	O
.	O
3	O
for	O
Nausori	O
PHC	O
to	O
$	O
2	O
.	O
6	O
for	O
CWMH	O
(	O
in	O
2020	O
values	O
).	O

Regarding	O
hLOS	O
and	O
PACU	O
-	O
LOS	O
differences	O
could	O
be	O
shown	O
.	O

To	O
reduce	O
overplotting	O
,	O
the	O
dataset	O
was	O
randomly	O
down	O
-	O
sampled	O
to	O
10	O
K	O
cells	O
and	O
then	O
uploaded	O
to	O
CITEViz	B-BT
.	O

Information	O
about	O
the	O
best	O
performing	O
definitions	O
of	O
IOH	O
regarding	O
30	O
-	O
day	O
mortality	O
,	O
hospital	O
length	O
of	O
stay	O
(	O
hLOS	O
),	O
and	O
postanesthesia	O
care	O
unit	O
length	O
of	O
stay	O
(	O
PACU	O
-	O
LOS	O
)	O
is	O
missing	O
.	O

Big	O
SHIFT	O
was	O
delivered	O
to	O
the	O
whole	O
population	O
of	O
the	O
Northern	O
Division	O
of	O
Fiji	O
,	O
one	O
of	O
four	O
primary	O
administrative	O
units	O
of	O
Fiji	O
(	O
2017	O
census	O
population	O
,	O
131	O
,	O
914	O
)	O
[	O
6	O
].	O

In	O
this	O
study	O
,	O
we	O
introduce	O
an	O
open	O
-	O
source	O
unsupervised	O
workflow	O
for	O
Automated	O
Target	O
Screening	O
(	O
ATS	O
)	O
of	O
both	O
GC	O
-	O
HRMS	O
and	O
LC	O
-	O
HRMS	O
data	O
and	O
validate	O
its	O
performance	O
against	O
a	O
manual	O
evaluation	O
in	O
TraceFinder	O
(	O
TF	O
)	O
and	O
batch	O
-	O
mode	O
evaluation	O
in	O
MZmine	B-BT
using	O
a	O
real	O
-	O
life	O
data	O
set	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
estimate	O
the	O
annual	O
direct	O
healthcare	O
costs	O
of	O
scabies	O
and	O
related	O
SSTIs	O
in	O
Fiji	O
,	O
a	O
middle	O
-	O
income	O
Pacific	O
country	O
with	O
high	O
burden	O
of	O
scabies	O
.	O

In	O
2016	O
,	O
the	O
Fiji	O
Government	O
annual	O
Health	O
Status	O
Report	O
reported	O
that	O
SSTIs	O
caused	O
4	O
.	O
3	O
%	O
of	O
mortality	O
within	O
the	O
country	O
[	O
10	O
].	O

For	O
those	O
prescribed	O
an	O
injection	O
,	O
we	O
used	O
benzathine	O
penicillin	O
(	O
for	O
impetigo	O
)	O
or	O
cloxacillin	O
(	O
for	O
cellulitis	O
,	O
abscess	O
,	O
or	O
severe	O
SSTI	O
)	O
as	O
recommended	O
by	O
Fiji	O
antibiotics	O
guidelines	O
[	O
16	O
].	O

To	O
investigate	O
the	O
influence	O
of	O
cultivating	O
HUVECs	O
with	O
APE	O
on	O
a	O
possible	O
inflammatory	O
activation	O
of	O
the	O
cells	O
,	O
the	O
release	O
of	O
the	O
pro	O
-	O
inflammatory	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
was	O
analysed	O
.	O

showed	O
that	O
APE	O
significantly	O
reduced	O
apoptosis	O
[	O
55	O
].	O

To	O
streamline	O
the	O
gating	O
process	O
,	O
we	O
developed	O
CITEViz	B-BT
which	O
allows	O
users	O
to	O
interactively	O
gate	O
cells	O
in	O
Seurat	O
-	O
processed	O
CITE	O
-	O
Seq	O
data	O
.	O

To	O
obtain	O
the	O
expected	O
annual	O
cases	O
in	O
other	O
Fiji	O
divisions	O
,	O
we	O
multiplied	O
the	O
annual	O
risk	O
of	O
cases	O
above	O
with	O
the	O
population	O
size	O
for	O
all	O
other	O
Fiji	O
divisions	O
(	O
752	O
,	O
973	O
based	O
on	O
2017	O
census	O
)	O
[	O
6	O
].	O

A	O
significantly	O
increased	O
metabolic	O
activity	O
was	O
observed	O
in	O
cells	O
cultured	O
with	O
100	O
µg	O
/	O
mL	O
APE	O
compared	O
to	O
50	O
and	O
200	O
µg	O
/	O
mL	O
APE	O
(	O
Figure	O
8	O
).	O

AP200	O
:	O
HUVECs	O
in	O
culture	O
medium	O
with	O
200	O
µg	O
/	O
mL	O
APE	O
extract	O
.	O

C	O
Screenshot	O
of	O
the	O
gating	O
page	O
in	O
CITEViz	B-BT
with	O
an	O
example	O
PBMC	O
CITE	O
-	O
seq	O
dataset	O
[	O
5	O
]	O

The	O
HUVECs	O
were	O
evaluated	O
at	O
least	O
12	O
h	O
after	O
APE	O
and	O
cell	O
culture	O
medium	O
supplementation	O
to	O
avoid	O
a	O
misinterpretation	O
of	O
the	O
morphological	O
state	O
of	O
the	O
endothelial	O
cells	O
[	O
21	O
].	O

We	O
used	O
the	O
average	O
household	O
size	O
in	O
Fiji	O
,	O
4	O
.	O
2	O
in	O
2021	O
[	O
18	O
],	O
to	O
quantify	O
the	O
number	O
of	O
tubes	O
that	O
would	O
be	O
sufficient	O
to	O
treat	O
the	O
whole	O
family	O
as	O
recommended	O
in	O
the	O
guidelines	O
.	O

CITEViz	B-BT
uniquely	O
supports	O
a	O
back	O
-	O
gate	O
function	O
.	O

Using	O
a	O
data	O
-	O
driven	O
approach	O
,	O
we	O
identified	O
the	O
best	O
fitting	O
definitions	O
of	O
IOH	O
for	O
30	O
-	O
day	O
mortality	O
,	O
hLOS	O
,	O
and	O
PACU	O
-	O
LOS	O
.	O

The	O
effect	O
of	O
APE	O
in	O
increasing	O
concentrations	O
(	O
0	O
µg	O
/	O
mL	O
,	O
50	O
µg	O
/	O
mL	O
,	O
100	O
µg	O
/	O
mL	O
,	O
and	O
200	O
µg	O
/	O
mL	O
)	O
on	O
the	O
CI	O
was	O
measured	O
.	O

Representative	O
immunofluorescence	O
images	O
of	O
paraformaldehyde	O
-	O
fixated	O
HUVECs	O
in	O
culture	O
medium	O
,	O
HUVECs	O
with	O
50	O
µg	O
/	O
mL	O
APE	O
,	O
HUVECs	O
with	O
100	O
µg	O
/	O
mL	O
APE	O
,	O
and	O
HUVECs	O
with	O
200	O
µg	O
/	O
mL	O
APE	O
85	O
h	O
after	O
seeding	O
(	O
40	O
×	O
primary	O
magnification	O
).	O

In	O
the	O
Skin	O
Health	O
Intervention	O
Fiji	O
Trial	O
(	O
SHIFT	O
)	O
conducted	O
between	O
2012	O
–	O
2013	O
,	O
scabies	O
prevalence	O
was	O
measured	O
at	O
36	O
.	O
4	O
%	O
and	O
impetigo	O
prevalence	O
at	O
23	O
.	O
4	O
%	O
among	O
residents	O
of	O
three	O
islands	O
of	O
Fiji	O
[	O
7	O
].	O

Project	O
name	O
:	O
CITEViz	B-BT

LOS	O
:	O
length	O
of	O
stay	O
,	O
PACU	O
:	O
postoperative	O
care	O
unit	O
,	O
BMI	O
:	O
body	O
mass	O
index	O
,	O
ASA	O
:	O
American	O
association	O
of	O
anesthesiologist	O
score	O
,	O
min	O
:	O
minutes	O
,	O
d	O
:	O
days	O
,	O
n	O
:	O
number	O
,	O
MAP	O
:	O
mean	O
arterial	O
pressure	O
,	O
IOH	O
:	O
intraoperative	O
hypotension	O

The	O
user	O
interface	O
and	O
internal	O
workflow	O
of	O
CITEViz	B-BT
uniquely	O
work	O
together	O
to	O
produce	O
an	O
organized	O
workflow	O
and	O
sensible	O
data	O
structures	O
for	O
easy	O
data	O
retrieval	O
.	O

At	O
a	O
minimum	O
,	O
CITEViz	B-BT
requires	O
a	O
Seurat	O
object	O
with	O
a	O
normalized	O
ADT	O
counts	O
matrix	O
.	O

Using	O
this	O
technique	O
,	O
we	O
identified	O
445	O
proteins	O
with	O
high	O
confidence	O
from	O
trace	O
amounts	O
of	O
highly	O
pure	O
spore	O
preparations	O
,	O
including	O
52	O
of	O
the	O
79	O
proteins	O
(	O
approximately	O
70	O
%)	O
previously	O
demonstrated	O
to	O
be	O
localized	O
in	O
spores	O
in	O
the	O
SubtiWiki	B-BT
database	O
and	O
detected	O
through	O
direct	O
protein	O
analysis	O
.	O

The	O
identified	O
proteins	O
also	O
included	O
52	O
(	O
70	O
%)	O
of	O
the	O
79	O
proteins	O
previously	O
annotated	O
as	O
""""	O
sporulation	O
proteins	O
""""	O
in	O
the	O
SubtiWiki	B-BT
database	O
and	O
found	O
in	O
direct	O
protein	O
analysis	O
(	O
marked	O
in	O
yellow	O
in	O
the	O
Supplementary	O
Table	O
S4	O
).	O

The	O
effect	O
of	O
APE	O
on	O
the	O
proliferation	O
of	O
HUVECs	O
was	O
assessed	O
in	O
real	O
-	O
time	O
by	O
the	O
xCELLigence	O
system	O
E	O
-	O
plate	O
16	O
(	O
ACEA	O
Biosciences	O
,	O
Inc	O
.,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
for	O
85	O
h	O
at	O
10	O
min	O
intervals	O
.	O

The	O
cost	O
of	O
surgical	O
procedures	O
was	O
not	O
estimated	O
separately	O
because	O
it	O
was	O
captured	O
in	O
the	O
unit	O
cost	O
of	O
admissions	O
in	O
the	O
Fiji	O
costing	O
study	O
[	O
20	O
].	O

HUVECs	O
cultured	O
with	O
APE	O
-	O
100	O
showed	O
the	O
significantly	O
lowest	O
prostacyclin	O
release	O
compared	O
to	O
APE	O
-	O
50	O
-	O
and	O
APE	O
-	O
200	O
-	O
treated	O
cells	O
(	O
Figure	O
9	O
).	O

CITEViz	B-BT
was	O
ultimately	O
designed	O
to	O
facilitate	O
novel	O
hypothesis	O
generation	O
,	O
and	O
is	O
available	O
to	O
download	O
on	O
GitHub	O
[	O
15	O
].	O

The	O
best	O
fitting	O
definitions	O
were	O
relative	O
time	O
with	O
a	O
MAP	O
(	O
mean	O
arterial	O
pressure	O
)	O
of	O
<	O
80	O
mmHg	O
for	O
30	O
-	O
day	O
mortality	O
,	O
lowest	O
MAP	O
for	O
one	O
minute	O
for	O
hLOS	O
,	O
and	O
lowest	O
MAP	O
for	O
one	O
cumulative	O
minute	O
for	O
PACU	O
-	O
LOS	O
.	O

Multivariable	O
regression	O
analyses	O
revealed	O
a	O
sigmoid	O
relationship	O
between	O
IOH	O
and	O
both	O
hLOS	O
and	O
PACU	O
-	O
LOS	O
(	O
Figs	O
4	O
and	O
5	O
).	O

Four	O
days	O
after	O
cell	O
seeding	O
,	O
LDH	O
release	O
was	O
significantly	O
lower	O
in	O
cell	O
cultures	O
treated	O
with	O
APE	O
-	O
50	O
and	O
APE	O
-	O
100	O
compared	O
to	O
that	O
in	O
the	O
untreated	O
control	O
.	O

Eighty	O
-	O
five	O
hours	O
after	O
cell	O
seeding	O
,	O
a	O
higher	O
number	O
of	O
viable	O
HUVECs	O
cultured	O
with	O
APE	O
-	O
100	O
and	O
APE	O
-	O
200	O
was	O
detected	O
compared	O
to	O
that	O
in	O
the	O
control	O
cells	O
.	O

Several	O
gating	O
schemes	O
were	O
used	O
to	O
show	O
the	O
utility	O
of	O
CITEViz	B-BT
and	O
to	O
identify	O
CD14	O
monocytes	O
,	O
CD4	O
T	O
-	O
cells	O
,	O
CD8	O
T	O
-	O
cells	O
,	O
Natural	O
Killer	O
(	O
NK	O
)	O
cells	O
,	O
B	O
-	O
cells	O
,	O
and	O
platelets	O
.	O

An	O
example	O
of	O
a	O
QC	O
metric	O
that	O
can	O
be	O
assessed	O
with	O
CITEViz	B-BT
is	O
the	O
number	O
of	O
unique	O
antibodies	O
detected	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
cell	O
seeding	O
,	O
a	O
significantly	O
increased	O
prostacyclin	O
release	O
was	O
observed	O
in	O
APE	O
-	O
200	O
-	O
treated	O
HUVECs	O
compared	O
to	O
untreated	O
and	O
APE	O
-	O
50	O
-	O
and	O
APE	O
-	O
100	O
-	O
treated	O
cells	O
(	O
Figure	O
9	O
).	O

This	O
study	O
uses	O
prospectively	O
collected	O
data	O
from	O
the	O
Northern	O
Division	O
of	O
Fiji	O
to	O
estimate	O
the	O
costs	O
of	O
healthcare	O
presentations	O
and	O
hospital	O
admissions	O
among	O
patients	O
with	O
scabies	O
and	O
scabies	O
-	O
related	O
SSTIs	O
prior	O
to	O
the	O
delivery	O
of	O
MDA	O
through	O
Big	O
SHIFT	O
.	O

Representative	O
image	O
of	O
paraformaldehyde	O
-	O
fixated	O
HUVECs	O
in	O
culture	O
medium	O
supplemented	O
with	O
100	O
µg	O
/	O
mL	O
APE	O
85	O
h	O
after	O
seeding	O
(	O
HUVECs	O
were	O
fluorescently	O
stained	O
threefold	O
,	O
the	O
actin	O
cytoskeleton	O
in	O
green	O
,	O
von	O
Willebrand	O
factor	O
in	O
red	O
,	O
and	O
genomic	O
DNA	O
in	O
blue	O
;	O
scale	O
bar	O
:	O
50	O
µm	O
).	O

The	O
estimated	O
annual	O
direct	O
healthcare	O
costs	O
of	O
scabies	O
and	O
related	O
SSTIs	O
in	O
Fiji	O
was	O
estimated	O
to	O
be	O
$	O
3	O
.	O
0	O
million	O
,	O
equivalent	O
to	O
2	O
.	O
4	O
%	O
of	O
government	O
revenues	O
allocated	O
to	O
health	O
in	O
2019	O
.	O

The	O
estimated	O
annual	O
healthcare	O
costs	O
of	O
scabies	O
and	O
related	O
SSTIs	O
in	O
Fiji	O
was	O
US	O
$	O
3	O
.	O
0	O
million	O
,	O
with	O
cost	O
per	O
capita	O
of	O
$	O
3	O
.	O
3	O
.	O

The	O
pattern	O
of	O
the	O
IL	O
-	O
6	O
release	O
of	O
HUVECs	O
with	O
APE	O
cultivation	O
was	O
very	O
similar	O
to	O
that	O
of	O
prostacyclin	O
.	O

In	O
contrast	O
,	O
CITEViz	B-BT
enhances	O
reproducibility	O
by	O
including	O
important	O
gating	O
metadata	O
such	O
as	O
surface	O
protein	O
markers	O
,	O
gate	O
coordinates	O
,	O
and	O
previous	O
filtration	O
steps	O
.	O
Table	O
1CITEViz	O
compared	O
to	O
Single	O
-	O
Cell	O
Virtual	O
Cytometer	O
,	O
iSEE	O
,	O
and	O
SeuratProgramsGatingBack	O
-	O
GatingMulti	O
-	O
Omic	O
Feature	O
/	O
QC	O
VisualizationPlatformCITEViz	O
✓✓✓	O
R	O
-	O
ShinySingle	O
-	O
Cell	O
Virtual	O
Cytometer	O
[	O
12	O
]✓––	O
Cascading	O
Style	O
Sheet	O
&	O
JavaScriptiSEE	O
[	O
13	O
]–––	O
R	O
-	O
ShinySeurat	O
[	O
5	O
]✓–✓	O
R	O
&	O
R	O
-	O
Shiny	O

(	O
A	O
)	O
Phase	O
contrast	O
image	O
;	O
(	O
B	O
)	O
dead	O
HUVECs	O
stained	O
with	O
PI	O
in	O
red	O
,	O
(	O
C	O
)	O
FDA	O
-	O
stained	O
HUVEC	O
monolayer	O
showing	O
viable	O
cells	O
in	O
green	O
;	O
(	O
D	O
)	O
HUVEC	O
monolayer	O
supplemented	O
with	O
50	O
µg	O
/	O
mL	O
APE	O
;	O
(	O
E	O
)	O
HUVEC	O
monolayer	O
supplemented	O
with	O
100	O
µg	O
/	O
mL	O
APE	O
;	O
(	O
F	O
)	O
HUVEC	O
monolayer	O
supplemented	O
with	O
200	O
µg	O
/	O
mL	O
APE	O
.	O

In	O
addition	O
to	O
NTS	O
and	O
SS	O
,	O
MZmine	B-BT
can	O
also	O
be	O
used	O
to	O
perform	O
targeted	O
analysis	O
by	O
incorporating	O
user	O
-	O
defined	O
lists	O
of	O
target	O
features	O
and	O
retention	O
times	O
to	O
annotate	O
peaks	O
.	O

SAC	O
and	O
BMC	O
tested	O
CITEViz	B-BT
prototypes	O
.	O

In	O
Fiji	O
,	O
scabies	O
is	O
often	O
initially	O
treated	O
with	O
traditional	O
medicines	O
,	O
and	O
many	O
individuals	O
only	O
seek	O
medical	O
care	O
for	O
prolonged	O
illness	O
or	O
when	O
a	O
secondary	O
skin	O
infection	O
develops	O
[	O
9	O
].	O

A	O
limitation	O
of	O
CITEViz	B-BT
pertains	O
to	O
data	O
sparsity	O
where	O
gating	O
cells	O
by	O
gene	O
expression	O
(	O
RNA	O
)	O
results	O
in	O
a	O
high	O
rate	O
of	O
data	O
dropout	O
[	O
14	O
].	O

MetaPathways	B-BT
v2	O
.	O
5	O
[	O
37	O
]	O
was	O
used	O
to	O
create	O
the	O
benchmark	O
CAMI	O
environment	O
PGDB	O
(	O
ePGDB	O
)	O
which	O
are	O
PGDBs	O
for	O
microbial	O
communities	O
[	O
38	O
].	O

Thus	O
,	O
in	O
the	O
present	O
study	O
,	O
the	O
reduced	O
synthesis	O
of	O
,	O
e	O
.	O
g	O
.,	O
prostacyclin	O
and	O
IL	O
-	O
6	O
(	O
after	O
100	O
µg	O
/	O
mL	O
APE	O
in	O
comparison	O
to	O
50	O
or	O
200	O
µ	O
/	O
mL	O
APE	O
)	O
could	O
be	O
associated	O
with	O
increased	O
proliferation	O
and	O
thus	O
stronger	O
growth	O
of	O
the	O
endothelial	O
cell	O
monolayer	O
.	O

The	O
Northern	O
division	O
has	O
the	O
highest	O
prevalence	O
of	O
scabies	O
and	O
impetigo	O
among	O
all	O
Fiji	O
divisions	O
–	O
with	O
1	O
.	O
3	O
higher	O
odds	O
of	O
scabies	O
and	O
impetigo	O
compared	O
with	O
those	O
in	O
other	O
divisions	O
[	O
8	O
].	O

APE	O
-	O
100	O
:	O
HUVECs	O
in	O
culture	O
medium	O
with	O
100	O
µg	O
/	O
mL	O
APE	O
.	O

While	O
IOH	O
had	O
less	O
influence	O
than	O
length	O
of	O
surgery	O
and	O
duration	O
from	O
hospital	O
admission	O
to	O
surgery	O
on	O
hLOS	O
,	O
it	O
had	O
as	O
much	O
influence	O
as	O
length	O
of	O
surgery	O
on	O
PACU	O
-	O
LOS	O
.	O

AP	O
-	O
100	O
:	O
HUVECs	O
in	O
culture	O
medium	O
with	O
100	O
µg	O
/	O
mL	O
APE	O
extract	O
.	O

Scabies	O
and	O
related	O
SSTIs	O
therefore	O
lead	O
to	O
a	O
heavy	O
economic	O
burden	O
in	O
Fiji	O
,	O
raising	O
the	O
potential	O
benefit	O
of	O
prevention	O
programs	O
such	O
as	O
MDA	O
.	O

APE	O
-	O
200	O
:	O
HUVECs	O
in	O
culture	O
medium	O
with	O
200	O
µg	O
/	O
mL	O
APE	O
.	O

To	O
date	O
,	O
in	O
vivo	O
toxicological	O
studies	O
of	O
APE	O
have	O
not	O
revealed	O
any	O
toxic	O
effects	O
on	O
kidney	O
,	O
liver	O
,	O
the	O
reproductive	O
system	O
,	O
or	O
body	O
physiology	O
during	O
or	O
after	O
the	O
administration	O
of	O
acute	O
or	O
chronic	O
doses	O
[	O
68	O
,	O
69	O
,	O
70	O
,	O
71	O
,	O
72	O
].	O

CITEViz	B-BT
compared	O
to	O
Single	O
-	O
Cell	O
Virtual	O
Cytometer	O
,	O
iSEE	O
,	O
and	O
Seurat	O

In	O
conclusion	O
,	O
CITEViz	B-BT
streamlines	O
the	O
flow	O
cytometry	O
gating	O
workflow	O
in	O
CITE	O
-	O
Seq	O
data	O
to	O
help	O
facilitate	O
novel	O
hypothesis	O
generation	O
.	O

Our	O
approach	O
also	O
assumes	O
that	O
healthcare	O
utilization	O
patterns	O
in	O
other	O
divisions	O
of	O
Fiji	O
were	O
consistent	O
with	O
those	O
observed	O
in	O
the	O
Northern	O
Division	O
.	O

A	O
secondary	O
function	O
of	O
CITEViz	B-BT
is	O
to	O
provide	O
basic	O
multi	O
-	O
omic	O
single	O
/	O
co	O
-	O
expression	O
feature	O
plots	O
and	O
quality	O
control	O
figures	O
to	O
allow	O
biologists	O
to	O
quickly	O
and	O
holistically	O
assess	O
CITE	O
-	O
Seq	O
data	O
.	O

In	O
countries	O
endemic	O
for	O
scabies	O
like	O
Fiji	O
,	O
patients	O
may	O
not	O
seek	O
treatment	O
of	O
scabies	O
unless	O
it	O
creates	O
a	O
significant	O
disturbance	O
to	O
their	O
quality	O
of	O
life	O
[	O
27	O
].	O

The	O
outpatient	O
visits	O
and	O
admission	O
unit	O
cost	O
estimates	O
from	O
the	O
Fiji	O
costing	O
study	O
includes	O
both	O
recurrent	O
costs	O
(	O
staff	O
time	O
and	O
overheads	O
)	O
and	O
capital	O
costs	O
(	O
building	O
,	O
equipment	O
,	O
beds	O
,	O
furniture	O
,	O
and	O
vehicles	O
).	O

Abbreviations	O
:	O
hLOS	O
:	O
hospital	O
length	O
of	O
stay	O
;	O
PACU	O
:	O
postanesthesia	O
care	O
unit	O
;	O
PACU	O
-	O
LOS	O
:	O
postanesthesia	O
care	O
unit	O
length	O
of	O
stay	O
;	O
n	O
,	O
number	O
.	O

To	O
estimate	O
the	O
quantities	O
of	O
medicines	O
,	O
we	O
supplemented	O
the	O
utilization	O
data	O
collected	O
in	O
the	O
trial	O
with	O
relevant	O
antibiotics	O
and	O
treatment	O
guidelines	O
for	O
scabies	O
and	O
SSTIs	O
in	O
Fiji	O
[	O
16	O
,	O
17	O
].	O

The	O
anti	O
-	O
inflammatory	O
effect	O
of	O
APE	O
may	O
also	O
contribute	O
to	O
the	O
improvement	O
of	O
endothelial	O
proliferation	O
.	O

Scabies	O
and	O
related	O
SSTIs	O
lead	O
to	O
a	O
heavy	O
economic	O
burden	O
in	O
Fiji	O
and	O
prevention	O
would	O
reduce	O
these	O
healthcare	O
costs	O
.	O

CITEViz	B-BT
is	O
an	O
R	O
-	O
Shiny	O
app	O
that	O
standardizes	O
the	O
gating	O
workflow	O
in	O
CITE	O
-	O
Seq	O
data	O
for	O
efficient	O
classification	O
of	O
cell	O
populations	O
.	O

CITEViz	B-BT
can	O
also	O
visualize	O
basic	O
quality	O
control	O
(	O
QC	O
)	O
metrics	O
allowing	O
for	O
a	O
rapid	O
and	O
holistic	O
evaluation	O
of	O
CITE	O
-	O
Seq	O
data	O
.	O

Figure	O
2	O
clearly	O
shows	O
that	O
the	O
addition	O
of	O
100	O
µg	O
/	O
mL	O
APE	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
HUVEC	O
density	O
already	O
after	O
48	O
h	O
(	O
25	O
%)	O
and	O
even	O
more	O
so	O
after	O
85	O
h	O
(	O
52	O
%)	O
of	O
culturing	O
compared	O
to	O
that	O
in	O
the	O
control	O
cells	O
.	O

We	O
used	O
this	O
perspective	O
because	O
public	O
provision	O
of	O
most	O
outpatient	O
and	O
inpatient	O
care	O
is	O
free	O
in	O
Fiji	O
and	O
user	O
fees	O
are	O
very	O
low	O
compared	O
with	O
the	O
overall	O
health	O
expenditure	O
in	O
government	O
facilities	O
[	O
12	O
].	O

For	O
example	O
,	O
we	O
used	O
CITEViz	B-BT
to	O
generate	O
a	O
feature	O
plot	O
,	O
revealing	O
a	O
distinctly	O
high	O
expression	O
in	O
the	O
CD8	O
T	O
-	O
cell	O
population	O
(	O
Fig	O
.	O

Costs	O
obtained	O
in	O
other	O
years	O
and	O
/	O
or	O
different	O
currencies	O
converted	O
to	O
Fijian	O
dollar	O
using	O
the	O
average	O
exchange	O
rate	O
in	O
that	O
year	O
[	O
21	O
],	O
adjusted	O
to	O
2020	O
prices	O
using	O
GDP	O
deflator	O
[	O
22	O
],	O
and	O
converted	O
back	O
to	O
US	O
$	O
using	O
2020	O
exchange	O
rates	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
cell	O
seeding	O
,	O
the	O
metabolic	O
activity	O
of	O
all	O
the	O
APE	O
-	O
treated	O
HUVECs	O
was	O
significantly	O
higher	O
than	O
100	O
%	O
and	O
thus	O
above	O
that	O
of	O
the	O
untreated	O
control	O
cells	O
.	O

To	O
efficiently	O
gate	O
cell	O
populations	O
in	O
CITE	O
-	O
Seq	O
data	O
,	O
we	O
developed	O
CITEViz	B-BT
.	O

The	O
unit	O
costs	O
per	O
diagnostic	O
test	O
,	O
outpatient	O
visit	O
,	O
admission	O
to	O
PHC	O
facilities	O
,	O
and	O
hospital	O
admission	O
were	O
obtained	O
from	O
a	O
Fiji	O
costing	O
study	O
[	O
20	O
].	O

First	O
,	O
we	O
used	O
one	O
subset	O
to	O
choose	O
the	O
best	O
fitting	O
definitions	O
of	O
IOH	O
for	O
the	O
outcomes	O
30	O
-	O
day	O
mortality	O
,	O
hLOS	O
,	O
and	O
PACU	O
-	O
LOS	O
.	O

BMI	O
:	O
body	O
mass	O
index	O
,	O
MAP	O
:	O
mean	O
arterial	O
pressure	O
,	O
PACU	O
:	O
postanesthesia	O
care	O
unit	O
.	O

The	O
localization	O
of	O
52	O
of	O
these	O
445	O
proteins	O
in	O
spores	O
is	O
listed	O
in	O
the	O
SubtiWiki	B-BT
database	O
(	O
Supplementary	O
Table	O
S5	O
).	O

The	O
highest	O
release	O
was	O
observed	O
in	O
APE	O
-	O
200	O
-	O
treated	O
HUVECs	O
compared	O
to	O
that	O
in	O
APE	O
-	O
100	O
-	O
treated	O
and	O
untreated	O
cells	O
.	O

These	O
extrapolated	O
number	O
of	O
cases	O
in	O
Fiji	O
were	O
multiplied	O
by	O
the	O
mean	O
costs	O
per	O
case	O
to	O
yield	O
the	O
annual	O
costs	O
.	O

APE	O
50	O
:	O
HUVECs	O
in	O
culture	O
medium	O
with	O
50	O
µg	O
/	O
mL	O
AP	O
extract	O
.	O

Unlike	O
other	O
programs	O
,	O
CITEViz	B-BT
fills	O
an	O
unmet	O
need	O
by	O
(	O
1	O
)	O
implementing	O
a	O
seamless	O
flow	O
cytometry	O
gating	O
workflow	O
and	O
(	O
2	O
)	O
generating	O
basic	O
multi	O
-	O
omic	O
plots	O
in	O
Seurat	O
-	O
processed	O
CITE	O
-	O
Seq	O
data	O
.	O

To	O
demonstrate	O
the	O
utility	O
of	O
this	O
program	O
,	O
CITEViz	B-BT
was	O
used	O
to	O
gate	O
the	O
major	O
cell	O
populations	O
in	O
a	O
PBMC	O
CITE	O
-	O
Seq	O
dataset	O
[	O
5	O
].	O

Currently	O
,	O
CITEViz	B-BT
accepts	O
Seurat	O
and	O
BioConductor	O
SingleCellExperiment	O
objects	O
.	O

A	O
study	O
by	O
Romani	O
[	O
8	O
]	O
indicated	O
that	O
scabies	O
and	O
impetigo	O
cases	O
were	O
prevalent	O
in	O
the	O
Northern	O
division	O
compared	O
with	O
other	O
Fiji	O
divisions	O
,	O
with	O
an	O
adjusted	O
odds	O
ratio	O
(	O
OR	O
)	O
of	O
1	O
.	O
3	O
for	O
each	O
disease	O
.	O

The	O
PACU	O
-	O
LOS	O
showed	O
very	O
similar	O
behavior	O
but	O
for	O
“	O
lowest	O
MAP	O
for	O
1	O
cumulative	O
minute	O
”	O
(	O
Fig	O
5	O
).	O

Compared	O
to	O
the	O
control	O
cells	O
(	O
46	O
,	O
720	O
.	O
0	O
±	O
6473	O
.	O
9	O
),	O
there	O
was	O
a	O
significant	O
increase	O
in	O
endothelial	O
cells	O
85	O
h	O
after	O
the	O
addition	O
of	O
APE	O
at	O
50	O
µg	O
/	O
mL	O
(	O
62	O
,	O
428	O
.	O
3	O
±	O
4035	O
.	O
8	O
)	O
and	O
at	O
100	O
µg	O
/	O
mL	O
(	O
70	O
,	O
931	O
.	O
1	O
±	O
4850	O
.	O
2	O
).	O

In	O
2019	O
,	O
about	O
US	O
$	O
144	O
million	O
from	O
the	O
Fiji	O
government	O
’	O
s	O
revenue	O
was	O
allocated	O
to	O
health	O
[	O
13	O
].	O

The	O
two	O
types	O
of	O
input	O
data	O
currently	O
supported	O
by	O
CITEViz	B-BT
are	O
(	O
1	O
)	O
an	O
R	O
Data	O
Serialized	O
(	O
RDS	O
)	O
file	O
containing	O
a	O
Seurat	O
object	O
,	O
or	O
(	O
2	O
)	O
an	O
RDS	O
file	O
with	O
a	O
SingleCellExperiment	O
object	O
derived	O
from	O
the	O
as	O
.	O
SingleCellExperiment	O
()	O
function	O
from	O
the	O
Seurat	O
library	O
.	O

One	O
limitation	O
of	O
the	O
CAMI	O
ePGDB	O
as	O
a	O
benchmark	O
is	O
that	O
it	O
is	O
automatically	O
generated	O
using	O
MetaPathways	B-BT
but	O
the	O
predictions	O
have	O
not	O
been	O
curated	O
so	O
it	O
can	O
be	O
said	O
that	O
the	O
results	O
demonstrate	O
more	O
how	O
similar	O
the	O
other	O
prediction	O
methods	O
are	O
with	O
MetaPathways	O
and	O
PathoLogic	O
than	O
their	O
actual	O
prediction	O
performance	O
.	O

Regarding	O
our	O
LOS	O
analyses	O
,	O
we	O
found	O
Lowest	O
MAP	O
for	O
one	O
minute	O
to	O
be	O
the	O
best	O
fitting	O
IOH	O
definition	O
for	O
hLOS	O
and	O
“	O
Lowest	O
MAP	O
for	O
one	O
cumulative	O
minute	O
”	O
to	O
be	O
the	O
best	O
fitting	O
IOH	O
definition	O
for	O
PACU	O
-	O
LOS	O
.	O

Thus	O
,	O
the	O
formation	O
of	O
cell	O
–	O
cell	O
and	O
cell	O
–	O
substrate	O
contacts	O
was	O
unaffected	O
by	O
the	O
addition	O
of	O
APE	O
.	O

Cells	O
cultured	O
with	O
APE	O
-	O
200	O
showed	O
no	O
differences	O
compared	O
to	O
the	O
control	O
cells	O
.	O

While	O
the	O
addition	O
of	O
APE	O
at	O
a	O
concentration	O
of	O
50	O
µg	O
/	O
mL	O
caused	O
no	O
change	O
in	O
monolayer	O
growth	O
compared	O
to	O
that	O
in	O
the	O
control	O
cells	O
(	O
p	O
=	O
0	O
.	O
60	O
),	O
the	O
cell	O
index	O
was	O
significantly	O
increased	O
by	O
22	O
%	O
85	O
h	O
after	O
the	O
addition	O
of	O
100	O
µg	O
/	O
mL	O
of	O
APE	O
compared	O
to	O
that	O
in	O
the	O
control	O
cells	O
(	O
p	O
=	O
0	O
.	O
0054	O
).	O

These	O
results	O
are	O
in	O
line	O
with	O
prior	O
analyses	O
and	O
suggest	O
that	O
the	O
flow	O
cytometry	O
-	O
like	O
gating	O
workflow	O
in	O
CITEViz	B-BT
provided	O
an	O
alternative	O
approach	O
to	O
easily	O
classify	O
clusters	O
in	O
CITE	O
-	O
Seq	O
data	O
[	O
5	O
].	O

CITEViz	B-BT
improves	O
upon	O
Seurat	O
by	O
displaying	O
relevant	O
parameters	O
and	O
plots	O
in	O
the	O
R	O
-	O
Shiny	O
interface	O
,	O
providing	O
an	O
efficient	O
user	O
experience	O
with	O
continuous	O
visual	O
feedback	O
.	O

Interestingly	O
,	O
the	O
lowest	O
LDH	O
release	O
also	O
occurred	O
in	O
HUVECs	O
treated	O
with	O
APE	O
-	O
100	O
.	O

We	O
used	O
Orbitrap	O
HRMS	O
data	O
of	O
surface	O
water	O
extracts	O
to	O
compare	O
the	O
Automated	O
Target	O
Screening	O
(	O
ATS	O
)	O
workflow	O
with	O
data	O
evaluations	O
performed	O
with	O
the	O
vendor	O
software	O
TraceFinder	O
and	O
the	O
established	O
semi	O
-	O
automated	O
analysis	O
workflow	O
in	O
the	O
MZmine	B-BT
software	O
.	O

MZmine	B-BT
(	O
version	O
2	O
.	O
51	O
)	O
was	O
used	O
for	O
comparing	O
the	O
peak	O
annotation	O
performance	O
of	O
ATS	O
to	O
a	O
sophisticated	O
(	O
semi	O
-)	O
automated	O
analysis	O
workflow	O
.	O

We	O
used	O
before	O
-	O
intervention	O
data	O
from	O
the	O
Big	O
SHIFT	O
trial	O
in	O
Fiji	O
and	O
extrapolated	O
these	O
costs	O
to	O
the	O
entire	O
country	O
.	O

CITEViz	B-BT
analysis	O
of	O
PBMC	O
CITE	O
-	O
Seq	O
data	O
.	O

Representative	O
examples	O
of	O
the	O
HUVEC	O
monolayers	O
of	O
the	O
control	O
culture	O
(	O
without	O
APE	O
)	O
and	O
the	O
culture	O
wit	O
APE	O
in	O
the	O
concentration	O
of	O
100	O
µg	O
/	O
mL	O
(	O
85	O
h	O
after	O
seeding	O
).	O

These	O
“	O
CHECK	O
”	O
cases	O
are	O
similar	O
to	O
the	O
peak	O
status	O
“	O
ESTIMATED	O
”	O
in	O
MZmine	B-BT
.	O

In	O
addition	O
to	O
evaluating	O
the	O
association	O
of	O
IOH	O
with	O
mortality	O
,	O
hLOS	O
,	O
and	O
PACU	O
-	O
LOS	O
,	O
we	O
assessed	O
the	O
degree	O
of	O
influence	O
of	O
IOH	O
and	O
adjustment	O
variables	O
on	O
these	O
outcomes	O
using	O
the	O
Brier	O
score	O
and	O
MSE	O
.	O

Thus	O
,	O
APE	O
could	O
be	O
applied	O
in	O
the	O
future	O
as	O
an	O
accelerator	O
of	O
endothelial	O
cell	O
proliferation	O
after	O
,	O
e	O
.	O
g	O
.,	O
stent	O
placement	O
or	O
atherosclerosis	O
.	O

CITEViz	B-BT
can	O
split	O
this	O
QC	O
metric	O
by	O
individual	O
patient	O
donors	O
,	O
which	O
clearly	O
displayed	O
a	O
significant	O
difference	O
between	O
patients	O
1	O
–	O
4	O
and	O
patients	O
5	O
–	O
8	O
with	O
a	O
padj	O
of	O
0	O
(	O
Tukey	O
HSD	O
)	O
(	O
Fig	O
.	O

APE	O
-	O
100	O
:	O
HUVECs	O
in	O
culture	O
medium	O
with	O
100	O
µg	O
/	O
mL	O
AP	O
extract	O
.	O

The	O
back	O
-	O
gate	O
function	O
of	O
CITEViz	B-BT
allows	O
users	O
to	O
interactively	O
explore	O
gates	O
and	O
feature	O
combinations	O
that	O
define	O
a	O
specific	O
cell	O
cluster	O
.	O

We	O
speculate	O
the	O
development	O
of	O
better	O
scRNA	O
sequencing	O
assays	O
(	O
and	O
their	O
multi	O
-	O
omic	O
variants	O
)	O
will	O
better	O
resolve	O
heterogeneous	O
cell	O
populations	O
in	O
the	O
future	O
,	O
so	O
CITEViz	B-BT
was	O
built	O
to	O
gate	O
cells	O
based	O
on	O
any	O
assays	O
(	O
RNA	O
,	O
ADT	O
,	O
SCT	O
)	O
and	O
features	O
to	O
accommodate	O
future	O
improvements	O
in	O
sequencing	O
technology	O
.	O

The	O
estimated	O
23	O
,	O
000	O
bed	O
days	O
in	O
our	O
study	O
represents	O
7	O
.	O
1	O
%	O
of	O
admissions	O
for	O
all	O
divisional	O
hospitals	O
in	O
Fiji	O
in	O
2017	O
(	O
3	O
.	O
6	O
%	O
of	O
divisional	O
and	O
specialist	O
hospital	O
admissions	O
).	O

For	O
ICU	O
,	O
used	O
an	O
average	O
of	O
ICU	O
bed	O
day	O
estimates	O
from	O
two	O
hospitals	O
in	O
the	O
Fiji	O
costing	O
study	O
[	O
20	O
]	O
in	O
the	O
base	O
case	O
,	O
so	O
these	O
two	O
estimates	O
served	O
as	O
our	O
low	O
/	O
high	O
value	O
for	O
sensitivity	O
analysis	O
.	O

It	O
can	O
therefore	O
be	O
concluded	O
that	O
the	O
release	O
of	O
IL	O
-	O
6	O
was	O
significantly	O
increased	O
by	O
culturing	O
the	O
cells	O
in	O
APE	O
-	O
50	O
and	O
APE	O
-	O
200	O
,	O
whereas	O
culturing	O
the	O
cells	O
in	O
APE	O
-	O
100	O
was	O
comparable	O
to	O
the	O
release	O
of	O
IL	O
-	O
6	O
from	O
untreated	O
HUVECs	O
.	O

We	O
converted	O
the	O
OR	O
to	O
risk	O
ratio	O
(	O
RR	O
)	O
using	O
the	O
formula	O
in	O
Zhang	O
and	O
Yu	O
[	O
24	O
],	O
and	O
multiplied	O
this	O
RR	O
WITH	O
the	O
risk	O
in	O
the	O
Northern	O
Division	O
to	O
derive	O
the	O
risk	O
for	O
other	O
Fiji	O
divisions	O
.	O

Furthermore	O
,	O
CITEViz	B-BT
can	O
be	O
adapted	O
to	O
accommodate	O
more	O
data	O
structures	O
in	O
future	O
updates	O
(	O
refer	O
to	O
Limitations	O
sub	O
-	O
section	O
in	O
Discussions	O
).	O

In	O
this	O
study	O
,	O
we	O
found	O
a	O
three	O
-	O
phase	O
association	O
of	O
IOH	O
with	O
postoperative	O
outcomes	O
as	O
follows	O
:	O
1	O
)	O
below	O
a	O
MAP	O
of	O
approximately	O
60	O
mmHg	O
,	O
hLOS	O
and	O
PACU	O
-	O
LOS	O
decreased	O
with	O
increasing	O
MAP	O
,	O
followed	O
by	O
2	O
)	O
a	O
plateau	O
between	O
60	O
and	O
75	O
mmHg	O
,	O
and	O
3	O
)	O
above	O
a	O
MAP	O
of	O
75	O
mmHg	O
,	O
hLOS	O
and	O
PACU	O
-	O
LOS	O
further	O
decreased	O
with	O
increasing	O
MAP	O
.	O

The	O
input	O
data	O
format	O
for	O
CITEViz	B-BT
is	O
a	O
pre	O
-	O
processed	O
Seurat	O
object	O
,	O
which	O
requires	O
a	O
basic	O
level	O
of	O
coding	O
skills	O
in	O
R	O
and	O
the	O
ability	O
to	O
follow	O
public	O
Seurat	O
vignettes	O
.	O

The	O
custom	O
Gate	O
class	O
in	O
CITEViz	B-BT
is	O
necessary	O
to	O
store	O
detailed	O
gating	O
information	O
in	O
an	O
organized	O
data	O
structure	O
.	O
Fig	O
.	O

The	O
central	O
objective	O
behind	O
the	O
development	O
of	O
scalepopgen	B-BT
was	O
to	O
create	O
workflows	O
that	O
provide	O
easy	O
accessibility	O
to	O
major	O
population	O
genomic	O
analyses	O
.	O

In	O
our	O
experience	O
,	O
we	O
found	O
CITEViz	B-BT
to	O
be	O
a	O
uniquely	O
collaborative	O
tool	O
that	O
leverages	O
the	O
strengths	O
of	O
both	O
bench	O
and	O
computational	O
scientists	O
to	O
explore	O
and	O
analyze	O
data	O
together	O
.	O

In	O
contrast	O
,	O
the	O
0	O
.	O
95	O
confidence	O
set	O
for	O
hLOS	O
contains	O
only	O
three	O
IOH	O
definitions	O
(	O
Lowest	O
MAP	O
for	O
1	O
minute	O
,	O
Lowest	O
MAP	O
for	O
1	O
cumulative	O
minute	O
,	O
and	O
Lowest	O
MAP	O
for	O
3	O
cumulative	O
minutes	O
)	O
and	O
that	O
for	O
PACU	O
-	O
LOS	O
contains	O
only	O
the	O
selected	O
Lowest	O
MAP	O
for	O
1	O
cumulative	O
minute	O
.	O

One	O
-	O
way	O
sensitivity	O
analysis	O
indicated	O
that	O
variations	O
in	O
the	O
cost	O
per	O
outpatient	O
visit	O
had	O
the	O
biggest	O
influence	O
on	O
the	O
total	O
cost	O
of	O
scabies	O
and	O
SSTIs	O
in	O
Fiji	O
(	O
Fig	O
2	O
).	O

We	O
extrapolated	O
case	O
numbers	O
to	O
all	O
Fiji	O
divisions	O
using	O
the	O
expected	O
annual	O
number	O
of	O
cases	O
in	O
the	O
Northern	O
Division	O
,	O
and	O
the	O
risk	O
ratio	O
(	O
RR	O
)	O
of	O
scabies	O
infestation	O
between	O
the	O
Northern	O
Division	O
and	O
other	O
divisions	O
.	O

Therefore	O
,	O
two	O
days	O
after	O
cell	O
seeding	O
,	O
no	O
cell	O
damage	O
caused	O
by	O
the	O
addition	O
of	O
the	O
APE	O
was	O
detected	O
.	O

We	O
extrapolated	O
the	O
total	O
annual	O
number	O
of	O
cases	O
and	O
direct	O
healthcare	O
costs	O
for	O
all	O
divisions	O
in	O
Fiji	O
based	O
upon	O
previous	O
scabies	O
and	O
impetigo	O
prevalence	O
data	O
across	O
all	O
divisions	O
.	O

From	O
a	O
health	O
system	O
perspective	O
,	O
the	O
estimated	O
annual	O
healthcare	O
costs	O
of	O
scabies	O
and	O
related	O
SSTIs	O
in	O
Fiji	O
was	O
US	O
$	O
3	O
.	O
0	O
million	O
.	O

CITEViz	B-BT
provides	O
basic	O
visualization	O
of	O
QC	O
metrics	O
and	O
single	O
/	O
multi	O
-	O
omic	O
feature	O
expression	O
plots	O
in	O
addition	O
to	O
its	O
primary	O
function	O
as	O
a	O
gating	O
workflow	O
in	O
CITE	O
-	O
Seq	O
data	O
.	O

Most	O
of	O
the	O
definitions	O
were	O
negatively	O
associated	O
with	O
mortality	O
,	O
hLOS	O
,	O
and	O
PACU	O
-	O
LOS	O
in	O
univariable	O
models	O
.	O

Project	O
home	O
page	O
:	O
https	O
://	O
github	O
.	O
com	O
/	O
maxsonBraunLab	O
/	O
CITEViz	B-BT

In	O
conclusion	O
,	O
CITEViz	B-BT
(	O
1	O
)	O
streamlines	O
the	O
gating	O
workflow	O
in	O
CITE	O
-	O
Seq	O
data	O
to	O
identify	O
cell	O
populations	O
and	O
(	O
2	O
)	O
facilitates	O
basic	O
visualization	O
of	O
multi	O
-	O
omic	O
,	O
single	O
-	O
cell	O
sequencing	O
data	O
.	O

B	O
Back	O
-	O
end	O
of	O
CITEViz	B-BT
.	O

The	O
highest	O
proliferation	O
was	O
achieved	O
after	O
the	O
addition	O
of	O
100	O
µg	O
/	O
mL	O
APE	O
.	O

Costs	O
are	O
calculated	O
using	O
an	O
ingredients	O
-	O
based	O
approach	O
and	O
then	O
extrapolated	O
to	O
the	O
national	O
level	O
using	O
epidemiological	O
data	O
from	O
Fiji	O
.	O

The	O
median	O
hospital	O
LOS	O
was	O
5	O
.	O
1	O
(	O
IQR	O
:	O
3	O
.	O
1	O
–	O
10	O
.	O
3	O
)	O
days	O
,	O
and	O
the	O
median	O
PACU	O
-	O
LOS	O
was	O
2	O
.	O
1	O
(	O
IQR	O
:	O
1	O
.	O
6	O
–	O
2	O
.	O
9	O
)	O
h	O
.	O

CITEViz	B-BT
is	O
intended	O
to	O
be	O
used	O
by	O
biologists	O
familiar	O
with	O
flow	O
cytometry	O
and	O
who	O
can	O
either	O
(	O
1	O
)	O
perform	O
basic	O
single	O
-	O
cell	O
analysis	O
or	O
(	O
2	O
)	O
collaborate	O
in	O
a	O
team	O
with	O
a	O
computational	O
scientists	O
.	O

The	O
445	O
identified	O
proteins	O
were	O
searched	O
against	O
the	O
SubtiWiki	B-BT
and	O
UniProt	O
B	O
.	O

Lastly	O
,	O
we	O
summed	O
up	O
the	O
number	O
of	O
cases	O
for	O
the	O
Northern	O
and	O
the	O
number	O
for	O
other	O
divisions	O
to	O
get	O
the	O
total	O
annual	O
number	O
of	O
cases	O
in	O
all	O
Fiji	O
divisions	O
.	O

The	O
main	O
objective	O
of	O
this	O
trial	O
was	O
to	O
find	O
the	O
best	O
fitting	O
definitions	O
of	O
IOH	O
and	O
their	O
associations	O
with	O
30	O
-	O
day	O
mortality	O
,	O
hospital	O
LOS	O
(	O
hLOS	O
),	O
and	O
postanesthesia	O
care	O
unit	O
(	O
PACU	O
)	O
LOS	O
in	O
a	O
general	O
surgical	O
population	O
at	O
a	O
large	O
academic	O
center	O
.	O

Since	O
neither	O
cell	O
–	O
cell	O
(	O
VE	O
-	O
cadherin	O
)	O
nor	O
cell	O
–	O
substrate	O
(	O
vinculin	O
)	O
binding	O
was	O
affected	O
by	O
APE	O
,	O
it	O
is	O
reasonable	O
to	O
assume	O
that	O
the	O
increase	O
in	O
endothelial	O
density	O
was	O
due	O
to	O
the	O
proliferation	O
of	O
HUVECs	O
.	O

The	O
LOS	O
and	O
PACU	O
-	O
LOS	O
datasets	O
were	O
subset	O
of	O
the	O
mortality	O
dataset	O
.	O

The	O
lowest	O
release	O
was	O
found	O
in	O
APE	O
-	O
100	O
-	O
treated	O
HUVECs	O
(	O
Figure	O
10	O
).	O

The	O
significantly	O
highest	O
release	O
was	O
observed	O
in	O
APE	O
-	O
50	O
-	O
treated	O
HUVECs	O
compared	O
to	O
control	O
and	O
APE	O
-	O
100	O
-	O
treated	O
cells	O
.	O

After	O
supplementation	O
of	O
the	O
culture	O
medium	O
with	O
APE	O
,	O
significantly	O
more	O
viable	O
HUVECs	O
adhered	O
compared	O
to	O
control	O
cells	O
(	O
see	O
Figure	O
2	O
,	O
nearly	O
no	O
death	O
cells	O
were	O
visible	O
),	O
the	O
damage	O
to	O
the	O
outer	O
cell	O
membrane	O
was	O
prevented	O
and	O
less	O
LDH	O
was	O
detected	O
in	O
the	O
culture	O
medium	O
compared	O
to	O
the	O
untreated	O
control	O
,	O
while	O
at	O
the	O
same	O
time	O
the	O
metabolic	O
activity	O
was	O
increased	O
,	O
hinting	O
at	O
an	O
increased	O
proliferation	O
of	O
the	O
HUVECs	O
.	O

To	O
analyse	O
the	O
influence	O
of	O
the	O
possible	O
damage	O
of	O
APE	O
on	O
HUVECs	O
,	O
the	O
integrity	O
of	O
the	O
outer	O
endothelial	O
cell	O
membrane	O
was	O
examined	O
.	O

CITEViz	B-BT
provides	O
basic	O
visualization	O
of	O
quality	O
control	O
(	O
QC	O
)	O
metrics	O
,	O
single	O
-	O
feature	O
,	O
and	O
feature	O
co	O
-	O
expression	O
plots	O
.	O

These	O
data	O
led	O
us	O
to	O
hypothesise	O
that	O
APE	O
can	O
influence	O
the	O
proliferation	O
of	O
HUVECs	O
and	O
the	O
formation	O
of	O
thrombi	O
.	O

The	O
application	O
of	O
CITEViz	B-BT
to	O
a	O
PBMC	O
CITE	O
-	O
Seq	O
dataset	O
[	O
5	O
]	O
led	O
to	O
the	O
identification	O
of	O
6	O
major	O
cell	O
populations	O
(	O
CD4	O
T	O
cells	O
,	O
CD14	O
monocytes	O
,	O
CD8	O
T	O
cells	O
,	O
NK	O
cells	O
,	O
B	O
cells	O
,	O
platelets	O
)	O
using	O
a	O
mix	O
of	O
one	O
-	O
or	O
two	O
-	O
step	O
gates	O
and	O
back	O
-	O
gates	O
(	O
Fig	O
.	O

The	O
secondary	O
function	O
of	O
CITEViz	B-BT
is	O
to	O
visualize	O
commonly	O
generated	O
plots	O
in	O
multi	O
-	O
omic	O
CITE	O
-	O
Seq	O
data	O
like	O
single	O
/	O
co	O
-	O
expression	O
plots	O
and	O
QC	O
metrics	O
.	O

These	O
release	O
responses	O
consistently	O
indicated	O
that	O
there	O
was	O
no	O
inflammatory	O
response	O
of	O
the	O
endothelial	O
cells	O
after	O
adding	O
100	O
µg	O
/	O
mL	O
APE	O
to	O
the	O
culture	O
medium	O
.	O

The	O
results	O
of	O
the	O
case	O
study	O
described	O
in	O
the	O
paper	O
are	O
hosted	O
at	O
:	O
https	O
://	O
bioinf2305	O
.	O
github	O
.	O
io	O
/	O
scalepopgen_results	B-BT
/.	O

The	O
Big	O
Skin	O
Health	O
Intervention	O
Fiji	O
Trial	O
(“	O
Big	O
SHIFT	O
”)	O
carried	O
out	O
surveillance	O
for	O
scabies	O
and	O
SSTIs	O
from	O
July	O
2018	O
to	O
June	O
2019	O
in	O
the	O
Northern	O
Division	O
of	O
Fiji	O
,	O
an	O
area	O
with	O
high	O
prevalence	O
of	O
scabies	O
,	O
prior	O
to	O
a	O
division	O
-	O
wide	O
ivermectin	O
-	O
based	O
mass	O
drug	O
administration	O
(	O
MDA	O
)	O
campaign	O
.	O

A	O
core	O
design	O
element	O
of	O
CITEViz	B-BT
is	O
the	O
Gate	O
class	O
—	O
a	O
custom	O
S4	O
class	O
written	O
in	O
base	O
R	O
(	O
Fig	O
.	O

Our	O
findings	O
are	O
likely	O
to	O
be	O
relevant	O
to	O
other	O
countries	O
in	O
the	O
Pacific	O
,	O
where	O
the	O
burden	O
of	O
scabies	O
and	O
the	O
costs	O
of	O
treatment	O
may	O
be	O
similar	O
to	O
that	O
of	O
Fiji	O
.	O

Compared	O
to	O
APE	O
-	O
200	O
-	O
and	O
APE	O
-	O
50	O
-	O
treated	O
cells	O
,	O
the	O
release	O
of	O
IL	O
-	O
6	O
by	O
APE	O
-	O
100	O
-	O
treated	O
cells	O
was	O
significantly	O
reduced	O
(	O
Figure	O
10	O
).	O

MZmine	B-BT
2	O
.	O
51	O
was	O
used	O
in	O
this	O
comparison	O
,	O
although	O
a	O
newer	O
version	O
MZmine	O
3	O
has	O
been	O
launched	O
during	O
the	O
preparation	O
of	O
the	O
present	O
study	O
.	O

It	O
can	O
therefore	O
be	O
concluded	O
that	O
the	O
cultivation	O
of	O
cells	O
with	O
APE	O
does	O
not	O
have	O
a	O
negative	O
effect	O
on	O
the	O
integrity	O
of	O
the	O
cell	O
membrane	O
and	O
does	O
not	O
induce	O
cell	O
damage	O
in	O
the	O
concentration	O
range	O
investigated	O
.	O

The	O
visualization	O
features	O
of	O
CITEViz	B-BT
were	O
used	O
to	O
investigate	O
cellular	O
heterogeneity	O
in	O
CD14	O
and	O
CD16	O
-	O
expressing	O
monocytes	O
and	O
to	O
detect	O
differential	O
numbers	O
of	O
detected	O
antibodies	O
per	O
patient	O
donor	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
seeding	O
,	O
the	O
significantly	O
highest	O
IL	O
-	O
6	O
release	O
was	O
found	O
for	O
HUVECs	O
treated	O
with	O
APE	O
-	O
200	O
compared	O
to	O
those	O
of	O
the	O
untreated	O
and	O
APE	O
-	O
100	O
-	O
treated	O
cells	O
.	O

